'Rapid Kill' Antibiotic Awaits US Data For Blanket Decolonization Prior To Surgery
This article was originally published in Scrip
Executive Summary
Destiny Pharma Ltd., a small UK antibiotic developer, and its lead "rapidly bactericidal" product XF-73, has placed itself firmly on the radar in the US. The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, is sponsoring and funding a clinical trial which is expected to complete in the coming weeks. If successful, XF-73 will be filed for the prevention of post-surgical Staphylococcal infections, a completely new indication. CEO Dr Bill Love explained to Scrip why the interest in Destiny's child.